RecruitingNCT06833541

Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease

Research on Gut-kidney Axis Regulation of Diabetic Kidney Disease Based on Multi-omics and Bacterio-drug Interaction Control Mechanism


Sponsor

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Enrollment

720 participants

Start Date

Apr 18, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Diabetic kidney disease (DKD) is characterized by high prevalence, multiple pathogenesis, and lack of effective treatment and management strategies. Early detection helps overcome treatment inertia, enables timely medical intervention, maximizes renal function in diabetic patients, and is essential to avoid renal failure and improve clinical outcomes. The gold standard for diagnosis of DKD is renal biopsy, which has the highest accuracy. However, due to the trauma of renal biopsy, the patient acceptance is low, the application scenario is not universal, and it is only used when it is difficult to distinguish diabetic nephropathy from non-diabetic nephropathy, and it is not the preferred diagnostic method for DKD. In the past decade, with the emergence and application of metabonomics, proteomics, genomics and other multi-omics techniques, more and more studies have recognized the prominent role of intestinal flora disorders and gut-derived metabolites in the occurrence of DKD. Therefore, from the perspective of intestinal flora, using multi-omics techniques to identify enterogenic metabolic markers of DKD and restore intestinal flora balance may be potential strategies for prevention and management of DKD. Modern medicine believes that intestinal flora is not only closely related to diet and digestion, participating in the synthesis, absorption and metabolism of nutrients, but also constituting intestinal barrier and participating in immune defense of the body. Its function is similar to the physiological function of "The spleen governs transportation and transformation". Based on the traditional Chinese medicine(TCM) pathogenesis of DKD "Spleen Failure to Disperse Essence and Poison Damage Kidney Collateral" proposed by the previous research group, this study intends to use microbiology-metabolomics to deeply study the TCM pathogenesis of DKD, provide scientific basis for it, and guide the theory of traditional Chinese medicine widely used in clinical work of prevention and treatment of diabetic nephropathy.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the role of gut bacteria (microbiota) and the chemical compounds they produce (metabolomics) in the development and progression of diabetic kidney disease — kidney damage caused by long-term diabetes. Researchers will compare gut microbiome profiles between patients with diabetic kidney disease and healthy volunteers to look for patterns. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with diabetic kidney disease meeting current Chinese clinical guidelines - You have type 2 diabetes and chronic kidney disease - OR you are a healthy volunteer with no history of serious infection, diabetes, obesity, or significant systemic illness **You may NOT be eligible if...** - You have a serious active infection (including HIV, hepatitis B/C, syphilis) - You are a healthy volunteer with diabetes, obesity (BMI above 30), or other significant health conditions - You have not provided informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06833541


Related Trials